← Eichor
Study identifier: NCT07499284 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia

Condition: Aplastic Anaemia  ·  Sponsor: The First Affiliated Hospital of Soochow University

PhaseNA
Planned participants224
Who can joinAll sexes, 14 Years to no upper limit
Healthy volunteersNo

About this study

Aplastic anemia (AA) is a bone marrow failure disorder characterized by pancytopenia and hypoplastic bone marrow caused by the decrease of hematopoietic stem cells. The pathogenesis of AA is complex and involves an abnormal hematopoietic microenvironment, hematopoietic stem cell/progenitor cell deficiencies and immunity disorders. Currently, the standard treatment for AA includes immunosuppressive therapy (IST) based on anti-thymocyte/lymphocyte globulin (ATG/ALG) and cyclosporine A (CsA) or hematopoietic stem cell transplantation (HSCT). Although HLA-identical sibling allogeneic hematopoietic stem cell transplantation is considered the preferred transplant option for patients with severe aplastic anemia (SAA), only less than 30% of patients have an available HLA-matched sibling donor. In recent years, haploidentical hematopoietic cell transplantation (Haplo-HCT) has developed rapidly and has become an important alternative. However, graft failure and graft-versus-host disease (GVHD) remain significant factors limiting its efficacy. Umbilical cord blood (UCB) contains a diverse population of hematopoietic stem cells. Compared with other sources, cord blood-derived hematopoietic stem cells are more primitive, more viable, and possess higher proliferative capacity. Therefore, cord blood transplantation, with its notable clinical therapeutic effects, has become an effective and reliable alternative to peripheral blood or bone marrow transplantation. Currently, some transplant…

This description comes directly from the study's public registry record.

Talk to the study team

Xiaojin Wu  ·  +8613057493105  ·  wuxiaojin@suda.edu.cn

Depei Wu  ·  +8613951102021  ·  wudepei@suda.edu.cn

Always discuss trial participation with your own doctor first.

Locations (4)

Hematology Department, The First Affiliated Hospital of Soochow UniversitySuzhou, Jiangsu, ChinaRecruiting
Suzhou Hongci Hematology HospitalSuzhou, Jiangsu, ChinaRecruiting
The Affiliated Hospital of Xuzhou Medical UniversityXuzhou, Jiangsu, ChinaRecruiting
The First Affiliated Hospital of Zhejiang Chinese Medical UniversityHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07499284